Organigram Reports Steep Q2 Profitability Decline, $5.8M Impairment, and Revised FCF Guidance
OGI is trading near its 52-week low of $1.11 (3.6% below the low).
Summary
Organigram Global reported a sharp drop in Q2 profitability and a $5.8 million impairment from U.S. hemp regulations, alongside a downgrade in free cash flow guidance, despite raising full-year revenue targets due to an acquisition.
Key Events · Earnings and Guidance · OGI
-
Q2 Profitability Plummets
Net revenue decreased 9% to $59.8 million, and Adjusted EBITDA fell 82% to $0.9 million year-over-year, resulting in a net loss of $0.9 million.
-
Significant Impairment Charge
The company recognized a $5.8 million impairment related to its U.S. hemp-derived products business due to new regulatory restrictions, which will effectively eliminate these products by November 2026.
-
Revised Fiscal 2026 Outlook
While full-year net revenue guidance was increased to exceed $350 million (incorporating the Sanity Group acquisition), free cash flow guidance was downgraded from positive to approximately break-even.
-
U.S. Cannabis Market Developments
The company is evaluating options for entering the U.S. medical cannabis market following the federal rescheduling of cannabis to Schedule III for approved products.
Analysis · OGI · Life Sciences
Organigram Global reported a significant decline in Q2 Fiscal 2026 profitability, with net revenue down 9% and Adjusted EBITDA plummeting 82% year-over-year, resulting in a net loss. The company also recognized a $5.8 million impairment charge related to its U.S. hemp-derived products business due to new regulatory restrictions. While full-year revenue guidance was raised due to the recent Sanity Group acquisition, free cash flow guidance was downgraded from positive to approximately break-even. The company is exploring options for the U.S. medical cannabis market following federal rescheduling.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.6% of the 978 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OGI was trading at $1.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $178.6M. The 52-week trading range was $1.11 to $2.24. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.